Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precipio Inc PRPO

Healthcare
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through... see more

Recent & Breaking News (NDAQ:PRPO)

Precipio Completes the Transaction with Poplar Healthcare's Oncometrix Hematopathology Division

GlobeNewswire March 16, 2020

Precipio achieves impressive initial results of Artificial Intelligence Decision-Support Tool

GlobeNewswire February 26, 2020

Precipio in advanced discussions with Poplar Healthcare towards a multi-faceted strategic partnership

GlobeNewswire February 18, 2020

TrialJectory and Precipio Partner to Provide Cancer Patients with First-of-its-Kind Diagnostic and Clinical Trial-Matching Service

PR Newswire January 28, 2020

Precipio Provides Clarification To Amendment No.1 to Form S-1 Filing

GlobeNewswire January 28, 2020

Precipio Provides Clarification To Recent S-1 Filing

GlobeNewswire January 15, 2020

Precipio announces shareholder update call to kick off 2020

GlobeNewswire January 13, 2020

Precipio Announces First IV-Cell Commercial Order from Northwell Health

Accesswire December 17, 2019

Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors

Accesswire December 4, 2019

Precipio Wins $750,000 Pharma Project

Accesswire November 14, 2019

Precipio Reports Superior Performance For IV-Cell(TM) In Side-By-Side Analysis Conducted by Two Major External Laboratories

Accesswire November 14, 2019

Precipio Announces Q3-2019 Corporate Update Call for Shareholders

Accesswire November 4, 2019

Partners HealthCare and Precipio Enter into Pathology Services Agreement

Accesswire October 9, 2019

Precipio Announces Shareholder Update Call on Commercial Progress

Accesswire October 2, 2019

First Substantial Customer: Tennessee Oncology Internalizes Precipio's HemeScreen(TM)

GlobeNewswire September 30, 2019

Clinical Validations for IV-Cell(TM) and HemeScreen(TM) Completed

GlobeNewswire September 26, 2019

Precipio and University of Pennsylvania Enter into Joint Collaboration Agreement for Pathology Diagnostics

GlobeNewswire September 5, 2019

Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019

GlobeNewswire August 13, 2019

Precipio Announces Q2-2019 Corporate Update Call for Shareholders

GlobeNewswire August 13, 2019

Global Expansion Efforts Begin Yielding Results

GlobeNewswire July 22, 2019